SURVODUTIDE

SURVODUTIDE

Precio habitual $115.00
Precio de venta: $115.00 Precio habitual: Venta: -0%

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim, currently one of the most closely watched compounds in metabolic disease research. Phase 3 clinical trial data from the SYNCHRONIZE-1 trial — published in 2026 — reported sustained weight loss of up to 16.6% over 76 weeks, placing it among the leading compounds in its class.

Mg: 10
En stock, listo para enviar
Cantidad

Survodutide (BI 456906) is a synthetic peptide functioning as a balanced dual agonist of the GLP-1 receptor and glucagon receptor (GcgR). It was designed to leverage complementary metabolic mechanisms: GLP-1R activation reduces caloric intake through central appetite signaling and promotes glucose-stimulated insulin secretion, while GcgR engagement is associated with increased energy expenditure, thermogenesis, and hepatic fat mobilization.

Dual Receptor Pharmacology Research
Research has examined survodutide's differential activity at GLP-1R and GcgR and the synergistic interactions between these two receptor pathways in preclinical and early clinical models.

Hepatic Metabolism and MASH Research
Preclinical and clinical research has examined survodutide in the context of metabolic dysfunction-associated steatohepatitis (MASH). The compound has been studied for its interactions with hepatic lipid accumulation, inflammation, and fibrosis signaling pathways.

Phase 3 Clinical Research
Survodutide progressed into Phase 3 clinical evaluation in the SYNCHRONIZE program. The SYNCHRONIZE-1 trial reported positive topline results in 2026, with participants experiencing average weight reductions of up to 16.6% over 76 weeks, meeting co-primary endpoints.

• Boehringer Ingelheim (2026). Survodutide met co-primary endpoints in SYNCHRONIZE-1 Phase III trial. Press release.
• Nahra R et al. (2021). Global Hepatic Biomarker Analysis with BI 456906 in Adults with Type 2 Diabetes. Diabetes Care, 44(4), 1042.

• Molecular Weight: ~4,317 g/mol
• CAS Number: 2414724-12-0
• Sequence / Structure: Dual GLP-1R / GcgR agonist peptide (BI 456906) — acylated, long-acting
• Form: Lyophilized powder
• Purity: ≥99% (HPLC verified)
• Storage: Per Certificate of Analysis

This compound has been independently tested by Brown Institute of Biomolecular Research. Click the link below to view the Certificate of Analysis for the current batch, including compound identity confirmation and purity verification.

View Certificate of Analysis

All compounds available through PEPTIVA.LIFE are research-grade products supplied for scientific and laboratory purposes. By completing a purchase, you confirm that you understand the nature of the product and accept responsibility for its appropriate use. PEPTIVA.LIFE operates as a chemical supplier. All sales are subject to our Terms and Conditions.